Effect of Traditional Chinese Medicine Combined with Bladder Perfusion with Hydroxycamptothecin on Color Ultrasound and Clinical Efficacy in Patients with Bladder Cancer Surgery

Objective. To observe the clinical effect of Xiaozheng Decoction combined with bladder perfusion with hydroxycamptothecin in the treatment of bladder cancer. Methods. A total of 92 bladder cancer patients admitted to our hospital from January to December 2018 were selected and divided into an observation group and a control group according to the random number table method, with 46 cases in each group. The observation group was given Xiaozheng Decoction combined with bladder perfusion with hydroxycamptothecin, and the control group was given hydroxycamptothecin. The levels of serum-related factors (intercellular adhesion molecule-1 (ICAM-1), E-cadherin, cell adhesion molecules (CAM), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF)), white blood cell (WBC) level, immune function indexes, short-term total response rate, and incidence of adverse reactions were compared between the two groups before and after treatment. Results. After 2 years of postoperative treatment, the levels of ICAM-1, E-cadherin, CAM-1, FGF, and VEGF (a, b, c) in both groups were improved compared with those before treatment and the observation group was better than the control group p < 0.01 . The number of WBCs was significantly higher than in the control group after Traditional Chinese Medicine (TCM) treatment. The observation group was better than the control group in increasing CD3+ and CD4+ levels and decreasing CD8+ level p < 0.05 , indicating that this prescription could improve the immune function of patients. The recurrence rate in the observation group was 6.52% after 2 years of treatment, lower than 17.39% in the control group. Color ultrasound parameters showed that there were no statistically significant differences in arrive time (AT) and time to peak (TTP) between patients with and without recurrence and peak intensity (PI) and washout time (WT) were higher in patients with recurrence than in patients without recurrence p < 0.01 . The incidence of adverse reactions was significantly lower than that of the control group p < 0.01 . Conclusion. The clinical effect of Xiaozheng Decoction combined with hydroxycamptothecin on the treatment of bladder cancer was clear and superior to that of hydroxycamptothecin, which could effectively improve the serological indicators of patients with a low incidence of adverse reactions and prolong the survival cycle of patients. Therefore, it is worthy of promotion and application.

Download Full-text

Treatment of knee osteoarthritis with traditional Chinese medicine sloughingClinical efficacy study

Journal of Integrative Medicine ◽

10.30564/jim.v8i2.2060 ◽

2020 ◽

Vol 8 (2) ◽

Author(s):

Liang Wen

Keyword(s):

Chinese Medicine ◽

Traditional Chinese Medicine ◽

Knee Osteoarthritis ◽

Western Medicine ◽

Clinical Effect ◽

Effective Rate ◽

Control Group ◽

Observation Group ◽

Group A ◽

Group B

Objective: To explore the clinical effect of the treatment of knee osteoarthritis with traditional Chinese medicine.Methods: 152 patients with knee osteoarthritis who were treated in our hospital from July 2018 to April 2020 were divided into two groups. Group A (control group) was treated with conventional western medicine, i.e. celecoxib 200 mg capsule +Glucosamine hydrochloride capsule 0.75g, group B (observation group): the treatment of traditional Chinese medicine sloughing using our experience formula, and further comparative evaluation of the treatment effect of the two groups. Results: the effective rate was 75% in the control group and 92% in the observation group. Conclusion: in the treatment of knee osteoarthritis, traditional Chinese medicine is more effective than western medicine.

Download Full-text

Clinical Effect Analysis of Jianpi Bushen Yiqi Decoction on Patients with Chronic Nephritis

Tobacco Regulatory Science ◽

10.18001/trs.7.5.57 ◽

2021 ◽

Vol 7 (5) ◽

pp. 1383-1388

Author(s):

Shujuan Mu ◽

Jun Chen ◽

Jing Chen ◽

Xue Li ◽

Yingxu Chen ◽

...

Keyword(s):

Renal Function ◽

Adverse Reactions ◽

Clinical Effect ◽

Effective Rate ◽

Urinary Protein ◽

Control Group ◽

Observation Group ◽

Chronic Nephritis ◽

Tcm Syndrome ◽

Better Than

Select the actual clinical effect of Jianpi Bushen Yiqi Decoction on patients with chronic nephritis. Methods: A total of 60 patients with chronic nephritis who were admitted to our hospital from January 2018 to January 2019 were selected. They were divided into 2 groups according to the admission order, 30 cases each. The control group was treated with conventional western medicine, and the observation group was treated with Jianpi Bushen Yiqi Decoction on the basis of the control group. The renal function indexes and urinary protein index, clinical efficacy, TCM syndrome scores, and adverse reactions were compared between the two groups. Result: There was no difference in renal function and urinary protein indexes between the two groups before treatment (P> 0.05). After treatment, the indicators in the observation group were better than those in the control group (P <0.05). The total effective rate of treatment in the observation group was higher than that in the control group (P <0.05). There was no difference in TCM syndrome scores between the first two groups (P> 0.05). After treatment, the indicators in the observation group were better than those in the control group (P <0.05). The overall incidence of adverse reactions in the observation group was lower than that in the control group (P <0.05). Conclusion: Jianpi Bushen Yiqi Decoction has a significant effect on chronic nephritis, which can effectively improve the renal function and urinary protein index of patients, with few adverse reactions and great application value.

Download Full-text

Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.36.4.1831 ◽

2020 ◽

Vol 36 (4) ◽

Author(s):

Xuewen Wo ◽

Jinyan Han ◽

Jiajia Wang ◽

Xinmin Wang ◽

Xiaoying Liu ◽

...

Keyword(s):

Plasma Level ◽

Cerebral Infarction ◽

Antiplatelet Therapy ◽

Adverse Reactions ◽

Dual Antiplatelet Therapy ◽

Acute Cerebral Infarction ◽

Control Group ◽

Observation Group ◽

Significant Difference ◽

Better Than

Objective: To observe the clinical efficacy of sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of elderly patients with acute cerebral infarction (ACI). Methods: One hundred and twenty-two elderly patients with ACI who were admitted to the department of neurology of our hospital at May 2016-August 2018 were selected grouped into a control group and an observation group by random number table method, 61 in each group. On the basis of conventional treatment, the patients in the control group were given dual antiplatelet therapy (aspirin enteric-coated tablets + clopidogrel bisulfate tablets), while the patients in the observation group were given sequential butylphthalide therapy on the basis of the control group. The clinical effects of the two groups were compared after four weeks of treatment, and the changes of National Institutes of Health Stroke Scale (NIHSS), ADL score, plasma 3-mercaptopyruvate sulphurtransferase (3-MST) and Amyloid β42 (Aβ42) levels and the occurrence of adverse reactions during treatment were recorded. Results: The clinical efficacy of the observation group was better than that of the control group (P<0.05). There was no significant difference in NIHSS and ADL scores between the two groups before treatment (P>0.05). After treatment, the NIHSS and ADL scores of the observation group were better than those of the control group (P<0.05). There was no significant difference in plasma levels of 3-MST and AB42 between the two groups before treatment (P>0.05). The level of plasma 3-MST in the observation group was higher than that in the control group, and the level of plasma Aβ42 was lower than that in the control group (P<0.05). No serious adverse reactions occurred during the treatment period in both groups. Conclusion: Butylphthalide sequential therapy combined with dual antiplatelet therapy is effective in the treatment of elderly ACI. It can effectively improve the plasma level of 3-MST and decrease the plasma level of Aβ42, which is conducive to improving the living ability and neurological function of patients and has high safety. doi: https://doi.org/10.12669/pjms.36.4.1831 How to cite this:Wo X, Han J, Wang J, Wang X, Liu X, Wang Z. Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction. Pak J Med Sci. 2020;36(4):---------. doi: https://doi.org/10.12669/pjms.36.4.1831 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Analysis of the clinical value of Baogan Lishui decoction and convetional western medicine in treating Hepatitis B cirrhosis refractory ascites

Journal of Clinical and Nursing Research ◽

10.26689/jcnr.v2i4.411 ◽

2018 ◽

Vol 2 (4) ◽

Author(s):

Huaide Lin

Keyword(s):

Chinese Medicine ◽

Hepatitis B ◽

Combination Treatment ◽

Western Medicine ◽

Clinical Effect ◽

Refractory Ascites ◽

Control Group ◽

Observation Group ◽

Quality And Safety ◽

Clinical Value

Objective: To investigate the clinical effect of combination treatment of Chinese medicine Baogan Lishui decoction and western medicine on hepatitis B cirrhosis related refactory ascites.Method: Control group was given conventional western medicine therapy while the observation group was given same conventional western medicine therapy with additional of Chinese medicine Baogan Lishui decoction.Result: The total effective of clinical treatment on hepatitis B cirrhosis related refractory ascites in observation group was higher than that of the control group which was 88.89% compared to 71.11%, respectively and it was significant different (p<0.05).Conclusion: The combination treatment of Chinese medicine Baogao Lishui decoction and conventional western medicine can significantly increased the treatment effect on hepatitis B cirrhosis refractory ascites, and thus increases the quality and safety of life.

Download Full-text

Analysis of Clinical Effect of Treating Arrhythmia with Stable Heart Granules

Advanced Emergency Medicine ◽

10.18686/aem.v2i1.3 ◽

2013 ◽

Vol 2 ◽

pp. 7

Author(s):

Li Liu

Keyword(s):

Clinical Practice ◽

Adverse Reactions ◽

Clinical Effect ◽

Total Effective Rate ◽

Effective Rate ◽

Control Group ◽

Observation Group ◽

The Difference ◽

And Control ◽

Group Observation

Objective: To study the clinical effect on the treatment of cardiac arrhythmia, and further guide the clinical treatment. Method: From January 2011 to January 2013, 100 patients with arrhythmia were randomly divided into observation group and control group with 50 cases in each group. Observation group patients given oral Stable heart granule treatment, while control group was treated with oral propafenone treatment. The therapeutic effect and adverse reactions of the two groups were observed and compared. Results: The total effective rate of the observation group was higher than control group and incidence of adverse reactions was lower than control group, the difference was statistically significant, p < 0.05. The use of stable heart particles in the treatment of arrhythmia produce significant effect. Conclusion: Clinical effect for Stable heart granule on arrhythmia was significant and should widely entrenched in clinical practice.

Download Full-text

Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

10.21203/rs.3.rs-306501/v1 ◽

2021 ◽

Author(s):

Jing Wu ◽

Hao Jiang ◽

Liting Chen ◽

Bingqi Yu ◽

Zhibing Wu

Keyword(s):

Qualitative Data ◽

Adverse Reactions ◽

Clinical Effect ◽

Objective Response ◽

Malignant Ascites ◽

Control Group ◽

Observation Group ◽

Improvement Rate ◽

Significant Difference

Abstract Objective：The purpose of this study is to retrospectively observe the clinical efficacy and adverse reactions of docetaxel hyperthermic intraperitoneal chemotherapy (HIPEC) combined with endostar in treatment of malignant ascites. Methods：56 cases of malignant ascites admitted to Zhejiang Hospital from July 2019 and October 2020 had received no less than second-line chemotherapy. The observation group (n = 29) was treated with endostar 60mg d1,4,7 Q3W intraperitoneal injection combined with docetaxel 60mg/m2 d4 HIPEC Q3W for 2 cycles. The control group (n = 27) was just treated with docetaxel 60mg/m2 d1 HIPEC Q3W for 2 cycles. The general clinical data and qualitative data of the treatment results were processed by SPSS26.0 using χ2 test, and quantitative data were processed by t test. When P < 0.05, statistical data can be considered statistically significant.Results：There were significant differences between the observation group and the control group in objective response rate (ORR) (65.5% vs 37.0%，P=0.033)，in the improvement rate of KPS (48.3% vs 22.2%, P=0.042)，also in the median control time (57dvs 45d，P=0.027). The incidence of III to IV adverse reactions was low, and no treatment-related death was observed. There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion：Endostar combined with docetaxel HIPEC has good clinical effect on malignant ascites and can improve patients’ quality of life, and the adverse reactions can be tolerated.

Download Full-text

Correlation Analysis of Huayu Tongmai Decoction Intervention and Prognosis Indexes of Patients with Carotid Atherosclerosis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/2739092 ◽

2021 ◽

Vol 2021 ◽

pp. 1-7

Author(s):

Guangqing Cheng ◽

Xiaoni Yan ◽

Fengmeng Wang ◽

Chao Chen

Keyword(s):

Chinese Medicine ◽

Traditional Chinese Medicine ◽

Carotid Atherosclerosis ◽

Blood Lipid ◽

Control Group ◽

Common Disease ◽

Observation Group ◽

Plaque Volume ◽

Female Ratio ◽

Hs Crp

Background. Carotid atherosclerosis (CAS) is a common disease which seriously threatens the health of senile patients. The studies have indicated that traditional Chinese medicine (TCM) may effectively improve the symptom of CAS, while the therapeutic effect of Huayu Tongmai decoction on CAS remains unclear. Thus, this study aimed to explore the correlation between traditional Chinese medicine Huayu Tongmai decoction intervention and prognosis indexes of patients with CAS. Methods. Ninety CAS patients admitted to Zibo TCM-Integrated Hospital from September 2018 to September 2020 were selected as the research object and randomly divided into the control group and the observation group according to the male-female ratio of 1 : 1. Patients in the control group accepted the atorvastatin intervention, and on this basis, patients in the observation group were further intervened with TCM Huayu Tongmai decoction. Before and after treatment, patients’ levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were measured by the enzyme photometric colorimetry; hypersensitive c-reactive protein (hs-CRP) levels were measured by the ELISA method; nitric oxide (NO) levels were measured by the nitrate reductase assay and endothelin-1 (ET-1) levels were measured by radioimmunoassay; and the right and left carotid internal diameter (CAD), intima-media thickness (IMT), and plaque volume were measured by carotid ultrasonography. Results. The TC, TG, and LDL-C levels significantly decreased in patients compared to those before intervention; compared with the control group, patients who accepted Huayu Tongmai decoction combined with atorvastatin saw more significant improvement in their blood lipid indexes ( P < 0.01 ); after intervention, patients’ hs-CRP and ET-1 levels dropped significantly while the NO level rose remarkably, and between the two groups, the improvement in levels of hs-CRP, ET-1, and NO of patients in the observation group was significantly better ( P < 0.01 ); it was concluded from the imaging diagnosis results that compared with using atorvastatin alone, the combined intervention could better improve patients’ CAD, IMT, and plaque volume. Conclusion. Huayu Tongmai decoction can effectively improve patients’ blood lipid, reduce inflammatory response, enhance levels of relevant regulatory factors of CAS, and alleviate the symptoms.

Download Full-text

Effect of Chinese Medicine on the Biological Behavior and Magnetic Resonance Imaging of Bladder Cancer

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/1124526 ◽

2021 ◽

Vol 2021 ◽

pp. 1-10

Author(s):

Hengxin Qi ◽

Yuefeng Pan ◽

Li Chen ◽

Rui Li ◽

Chonghua Wang ◽

...

Keyword(s):

Quality Of Life ◽

Magnetic Resonance Imaging ◽

Bladder Cancer ◽

Chinese Medicine ◽

Biological Behavior ◽

Control Group ◽

Observation Group ◽

Resonance Imaging ◽

Bladder Irrigation

Objective. This study aimed to investigate the effects of traditional Chinese medicine (TCM) on biological behavior and magnetic resonance imaging and recurrence rate of patients with bladder cancer. Method. Forty-seven postoperative bladder cancer patients treated in our hospital who met the criteria were selected and randomly divided into the TCM treatment group (observation group) and the group without TCM treatment (control group). In the TCM treatment group, the prescription was slightly adjusted according to the different symptoms, and the main prescription remained unchanged. According to the treatment plan, patients continued to undergo bladder irrigation chemotherapy plus TCM treatment, while the control group was only treated with bladder irrigation chemotherapy. The number of patients with recurrence at 3 and 6 months and 1 year, the effects on patients’ clinical symptoms, and quality of life were observed, respectively. The changes in MRI images, blood routine, immune function, and leukocyte level and other related indexes before and after treatment were compared between the two groups. Results. After the patients in the observation group were treated with traditional Chinese medicine, the patients’ quality of life significantly improved. The patients’ CD3+, CD4+, and CD4+/CD8+ indexes were significantly higher than those of the control group. The levels of Hb and PLT of the patients in the observation group were significantly lower than those of the patients in the control group. Patients in the observation group had higher leukocyte levels and a lower recurrence rate than patients in the control group. Conclusion. TCM with chemotherapy drugs can effectively improve patients’ immune function, increase the level of T-lymphocyte subpopulation, and improve bone marrow hematopoietic function, which has a significant effect on the prevention and treatment of bladder cancer recurrence after surgery.

Download Full-text

Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.36.7.1964 ◽

2020 ◽

Vol 36 (7) ◽

Author(s):

Li Kong ◽

Kai Zuo ◽

Long Ma

Keyword(s):

Bone Mineral Density ◽

Zoledronic Acid ◽

Bone Mineral ◽

Adverse Reactions ◽

Clinical Effect ◽

Control Group ◽

Observation Group ◽

Mineral Density ◽

Senile Osteoporosis ◽

Significant Difference

Objective: To investigate the clinical efficacy of zoledronic acid in the treatment of senile osteoporosis. Methods: One hundred and six cases of senile osteoporosis who visited to our hospital from August 2017 to December 2018 for treatment were selected and randomly divided into a control group and an observation group. The control group was treated with conventional therapy, while the observation group was treated with zoledronic acid in addition to the treatment of the control group. Bone mineral density, pain degree, therapeutic effect and adverse reactions of the two groups were compared. Results: The total effective rate of the observation group was 96.67%, higher than 80.00% of the control group (P<0.05); the bone mineral density of lumbar vertebrae, femoral neck and Ward’ area in the two groups increased after 6 months of treatment, and the bone mineral density of the observation group increased more than that of the control group (P<0.05); the pain degree of the observation group was lower than that of the control group after 6 months of treatment, and the difference was significant (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P>0.05). Conclusion: Zoledronic acid is helpful to alleviate clinical symptoms, reduce the degree of bone pain, and promote the increase of bone mass, and has high safety in the treatment of senile osteoporosis, which is worth promotion. doi: https://doi.org/10.12669/pjms.36.7.1964 How to cite this:Kong L, Zuo K, Ma L. Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis. Pak J Med Sci. 2020;36(7):1703-1707. doi: https://doi.org/10.12669/pjms.36.7.1964 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Traditional Chinese medicine auricular point acupressure for the relief of pain, fatigue, and gastrointestinal adverse reactions after the injection of novel coronavirus-19 vaccines: a structured summary of a study protocol for a multicentre, three-arm, single-blind, prospective randomized controlled trial

Trials ◽

10.1186/s13063-021-05138-3 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Qinwei Fu ◽

Hui Xie ◽

Li Zhou ◽

Xinrong Li ◽

Yang Liu ◽

...

Keyword(s):

Chinese Medicine ◽

Traditional Chinese Medicine ◽

Injection Site ◽

Joint Pain ◽

Adverse Reactions ◽

Control Group ◽

Auricular Point ◽

Full Protocol ◽

Novel Coronavirus ◽

Single Blind

Abstract Objectives To investigate if traditional Chinese medicine (TCM) auricular point acupressure (APA) can alleviate and (or) reduce the pain (including injection site pain, headache, other muscle and joint pain), fatigue, and gastrointestinal adverse reactions (including nausea, vomiting, diarrhea), after the injection of novel coronavirus-19 vaccines (NCVs). Trial design The study is designed as a multicentre, parallel-group, three-arm, single-blind, prospective, randomized (1:1:1 ratio) study. Participants More than 360 participants will be recruited from healthy people who vaccinate NCVs in 5 community healthcare centres in the Sichuan province of China and 1 university hospital (Hospital of Chengdu University of Traditional Chinese Medicine). Inclusion criteria: ①Vaccinators meets the conditions of NCVs injection and have no contraindications to it. The details shall be subject to the instructions of the NCVs used and the statement of medical institutions. The first dose of NCVs injection shall be completed within 24 hours from the time of injection to the time of enrolment; ②No redness, swelling, injury or infection of the skin or soft tissue of both ears, which is not suitable for APA; ③No history of alcohol and adhesive tape contact allergy; ④18-59 years old, regardless of gender; ⑤Those who were able to complete the questionnaire independently at the time of the first and second dose of NCVs and on the 3rd, 7th and 15th day after the first and second dose of NCVs respectively; ⑥Those who agree to participate in the trial and sign the informed consent, and can seriously abide by the precautions after the injection of NCVs and the requirements of traditional Chinese medicine auricular point plasters sticking and acupressure. Exclusion criteria: ①Those who are not suitable to be vaccinated because they belong to the contraindication or cautious population; ②Those who have participated in other clinical trials within 4 weeks before the start of this study; ③No chronic/habitual/persistent headache, Muscle or joint pain, fatigue, diarrhea, nausea, retching or vomiting before the injection of NCVs, and no related diseases present (details of this item is listed in full protocol); ④Those who are in use or have received TCMAPA within 2 weeks before the trial; ⑤Pregnant or lactating women; ⑥Participants with other serious primary diseases and psychosis. Intervention and comparator ①Auricular point acupressure group: participants receive bilateral, symptom-specific TCMAPA in 5 auricular points (per side, 10 points bilateral) for 5 days, 3-4 times (about 1 min each time) of self-acupressure per day, after each NCVs injection (10 days in total). ②Sham auricular point acupressure group: participants receive bilateral, none symptom-specific, sham APA in 5 auricular points (per side, 10 points bilateral) for 5 days, 3-4 times (about 1 min each time) of self-acupressure per day, after each NCVs injection (10 days in total). ③Blank control group: Non-intervention blank control. The Hebei medical device Co. Ltd, Hebei, China manufactured the auricular point sticking plasters. Main outcomes Primary outcomes are all scores of visual analogue scale (VAS) based on subjective judgment of the participants included, including VAS score of pain at injection site, headache, muscle and joint pain, fatigue, nausea, retching, vomiting and diarrhea. Time points for outcomes above are the same: ①Immediately after first and second injection of the vaccine (Baseline assessment); ②Three days after first and second injection of the vaccine; ③Seven days after first and second injection of the vaccine; ④Fifteen days after first and second injection of the vaccine. Randomisation Participants will be randomized in 1:1:1 ratio to each group by computerized random number generator, and independently in each sub-centre. Blinding (masking) Participants, information collectors and statistical evaluators will be blinded between APA group and sham APA group. No blinding in the control group. Numbers to be randomised (sample size) No less than 360 participants will be randomized in 1:1:1 ratio to each group. Trial Status Protocol version 2.0 of February 3rd, 2021. Recruitment is expected to start on February 18th, 2021, and to finish on March 12th, 2021. Trial registration This trial was registered in the China Clinical Trial Registry (ChiCTR) (ChiCTR2100043210) on 8th February, 2021. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

Download Full-text